Centessa Pharmaceuticals Nasdaq ADSs Removed from Listing

Centessa Pharmaceuticals plc notified Nasdaq of the removal of its American Depositary Shares from listing and registration on the Nasdaq Stock Market LLC pursuant to 17 CFR 240.12d2-2.

Rhea-AI Filing Summary

Centessa Pharmaceuticals plc notified Nasdaq of the removal of its American Depositary Shares from listing and registration on the Nasdaq Stock Market LLC pursuant to 17 CFR 240.12d2-2. The filing states the removal follows Exchange and issuer compliance with the cited Nasdaq rules governing voluntary withdrawal.

Key Figures

Commission File Number: 001-40445 Rule citation: 17 CFR 240.12d2-2 Issuer phone number: +447391789784

3 metrics

Commission File Number 001-40445 Issuer filing identifier

Rule citation 17 CFR 240.12d2-2 Governing removal/withdrawal procedure

Issuer phone number +447391789784 Issuer principal executive offices contact

Key Terms

Form 25, American Depositary Shares, 17 CFR 240.12d2-2

3 terms

Form 25 regulatory

"FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION"

A Form 25 is an official filing with the U.S. Securities and Exchange Commission used to remove a company's stock or other security from a national exchange list. Investors should care because delisting often means less visibility, lower trading volume and wider price swings—similar to a product moving from a major supermarket to a small local market, which can make buying, selling and valuing the security more difficult.

American Depositary Shares market

"American Depositary Shares (Description of class of securities)"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

17 CFR 240.12d2-2 regulatory

"Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules"

A U.S. Securities and Exchange Commission rule that describes the conditions and procedural steps for a security to be removed from public registration or reporting under the Securities Exchange Act of 1934. For investors, it matters because it explains when a company’s shares can stop being subject to regular disclosure and exchange listing rules — similar to knowing when a publicly tracked product will be discontinued and no longer send updates, which affects transparency and liquidity.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why did Centessa Pharmaceuticals (CNTA) file a Form 25?

The filing notifies Nasdaq of removal of Centessa's American Depositary Shares from listing. It states the removal is made "pursuant to 17 CFR 240.12d2-2" and that both the Exchange and the issuer complied with applicable Nasdaq rules governing voluntary withdrawal.

What class of security is affected for CNTA?

The affected class is Centessa's American Depositary Shares. The Form 25 identifies that specific class and confirms Nasdaq has complied with the rules to strike the class from listing and/or withdraw registration.

Does the Form 25 state whether the withdrawal was voluntary for CNTA?

Yes. The filing references compliance with 17 CFR 240.12d2-2(c), indicating the issuer complied with Exchange rules and the requirements governing voluntary withdrawal of the class from listing and registration.

Will shareholders receive proceeds or consideration from this filing?

This Form 25 is a listing/registration notification and does not describe any proceeds. It certifies compliance with Nasdaq rules for withdrawal and does not state any cash or consideration to shareholders.

Who signed the Form 25 on behalf of Nasdaq in the CNTA filing?

The filing shows it was signed on behalf of Nasdaq by Katelin Rowe, listed with the title "cdo analyst" in the signature block included in the notification.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/24/2026 - 09:52 AM EDT Learn about SEC filing dates

UNITED STATES

OMB APPROVAL

OMB Number:			3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:			1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-40445

Issuer:	Centessa Pharmaceuticals plc
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	3rd Floor, 1 Ashley Rd
	Altrincham
	Cheshire	UNITED KINGDOM	WA14 2DT
Telephone number:					+447391789784

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

American Depositary Shares

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2026-06-24	By	katelin rowe		cdo analyst
Date		Name		Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.